Norges Bank
CERE

Norges Bank’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Norges Bank’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,335,746
Closed -$95.5M – 1987
2024
Q2 		$95.5M Buy
2,335,746
+1,610,692
+222% +$67.1M 0.01% 653
2024
Q1 		$30.6M Buy
725,054
+39,360
+6% +$1.65M ﹤0.01% 1139
2023
Q4 		$29.1M Buy
685,694
+138,723
+25% +$3.99M 0.01% 1152
2023
Q3 		$11.9M Buy
546,971
+161,259
+42% +$4.04M ﹤0.01% 1401
2023
Q2 		$12.3M Sell
385,712
-36,424
-9% -$1.12M ﹤0.01% 1454
2023
Q1 		$10.3M Buy
422,136
+247,598
+142% +$7.27M ﹤0.01% 1570
2022
Q4 		$5.5M Buy
174,538
+100,695
+136% +$2.84M ﹤0.01% 1755
2022
Q3 		$2.09M Buy
+73,843
New +$2.2M ﹤0.01% 1908
2021
Q3 		– Sell
-158,852
Closed -$4.07M – 2356
2021
Q2 		$4.07M Buy
+158,852
New +$2.27M ﹤0.01% 1934

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Norges Bank's CERE Position: Q3 2024 in Review

Norges Bank sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 2,335,746 shares — an estimated $95.5M sold.

Norges Bank first reported a position in CERE in Q2 2021 and held it in 9 quarters. The position peaked at $95.5M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Norges Bank reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Norges Bank sold 2,335,746 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $95.5M.
  • Norges Bank first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
  • Norges Bank's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $95.5M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Norges Bank's 13F filing for Q3 2024, filed 13 Nov 2024.